Vanguard Russell 2000 ETF

Most Recent

  • uploads///Analysts Reco ATRA
    Company & Industry Overviews

    Where Atara Biotherapeutics Stands This January: Analyst Ratings

    Atara Biotherapeutics (ATRA) is a company focused on developing novel T-cell immunotherapy treatments for patients with cancer and multiple sclerosis.

    By Kenneth Smith
  • uploads///AXDX revenue growth
    Company & Industry Overviews

    Does Accelerate Diagnostics’ Financial Performance Bode Well?

    The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Decoding the Advisory Board’s Net Profit Margins in 2017

    In 1Q17, the Advisory Board (ABCO) reported adjusted EBITDA of ~$45 million, which was higher than its guidance of $37 million–$42 million.

    By Margaret Patrick
  • uploads///
    Earnings Report

    Word on the Street: What Analysts Think about SHAK after 1Q16

    SHAK’s better-than-expected 1Q16 results led analysts to increase their consensus median price target for the next 12 months from $40.4 to $41.3.

    By Rajiv Nanjapla
  • uploads///
    Earnings Report

    What Are Analysts Recommending for Shake Shack?

    Of the ten analysts surveyed, 20% have “buy” recommendations for Shake Shack (SHAK), 60% have “hold” recommendations, and 20% have “sell” recommendations.

    By Rajiv Nanjapla
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.